Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 3;71(22):734-742.
doi: 10.15585/mmwr.mm7122e1.

Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

Agam K Rao et al. MMWR Morb Mortal Wkly Rep. .

Erratum in

Abstract

Certain laboratorians and health care personnel can be exposed to orthopoxviruses through occupational activities. Because orthopoxvirus infections resulting from occupational exposures can be serious, the Advisory Committee on Immunization Practices (ACIP) has continued to recommend preexposure vaccination for these persons since 1980 (1), when smallpox was eradicated (2). In 2015, ACIP made recommendations for the use of ACAM2000, the only orthopoxvirus vaccine available in the United States at that time (3). During 2020-2021, ACIP considered evidence for use of JYNNEOS, a replication-deficient Vaccinia virus vaccine, as an alternative to ACAM2000. In November 2021, ACIP unanimously voted in favor of JYNNEOS as an alternative to ACAM2000 for primary vaccination and booster doses. With these recommendations for use of JYNNEOS, two vaccines (ACAM2000 and JYNNEOS) are now available and recommended for preexposure prophylaxis against orthopoxvirus infection among persons at risk for such exposures.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Brett W. Petersen reports travel support from vaccine manufacturer Bavarian Nordic to participate in the Orthopox Viruses, Risk, Epidemiology, and Vaccine Response seminar in London, England. Stuart N. Isaacs reports salary support from the Perelman School of Medicine, University of Pennsylvania; grant support from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) to conduct an international poxvirus conference; institutional support from BioNTech to investigate mRNA-based subunit vaccines against poxviruses; and payment from UpToDate to author chapters on orthopoxviruses. Pablo J. Sánchez reports grant support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and NIAID, NIH. No other potential conflicts of interest were disclosed.

References

    1. CDC. Recommendation of the Immunization Practices Advisory Committee (ACIP). Smallpox vaccine. MMWR Morb Wkly Rep 1980;29:417–20. https://stacks.cdc.gov/view/cdc/1458
    1. Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva, Switzerland: World Health Organization; 1988. https://apps.who.int/iris/handle/10665/39485
    1. Petersen BW, Harms TJ, Reynolds MG, Harrison LH. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses—recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep 2016;65:257–62. 10.15585/mmwr.mm6510a2 - DOI - PubMed
    1. Satheshkumar PS, Damon IK. Poxviruses. In: Howley PM, Knipe DM, Damania BA, Cohen JI, eds. Fields virology: DNA viruses, vol 2. 7th ed. Philadelphia, PA: Wolters Kluwer; 2021.
    1. MacNeil A, Reynolds MG, Damon IK. Risks associated with vaccinia virus in the laboratory. Virology 2009;385:1–4. 10.1016/j.virol.2008.11.045 - DOI - PubMed